Navigation Links
Xanodyne's New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
Date:4/2/2009

NEWPORT, Ky., April 2 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review status for its investigational proprietary formulation of tranexamic acid for the treatment of women with menorrhagia, heavy menstrual bleeding (HMB), and its accompanying symptoms. On January 30, 2009, Xanodyne submitted the New Drug Application (NDA) for XP12B, a unique oral therapy which acts as a competitive plasmin inhibitor to prevent fibrinolysis by binding to the lysine receptor sites of plasminogen. This helps to normalize the hyperfibrinolytic activity often present in women with HMB.

"We are pleased with the position that the FDA has taken in granting XP12B a priority review as it reflects their recognition of the important unmet medical need which HMB represents. We look forward to working closely with the agency to further advance this important treatment option to women who suffer from menorrhagia, or heavy menstrual bleeding," said Gary A. Shangold, Chief Medical Officer of Xanodyne.

Under the Prescription Drug User Fee Act (PDUFA), drug products with priority review designation have a 6 month review clock as compared to a 10 month standard review. Upon approval, this product candidate could become the first approved pharmaceutical product in the United States specifically indicated for the treatment of menorrhagia.

About Menorrhagia

HMB, or menorrhagia, represents a frequent and significant medical condition encountered by obstetricians, gynecologists and primary care physicians. Menorrhagia has been described as regular, normal intervals of menstruation with excessive volume that may exceed 80 milliliters of blood loss per menstrual cycle. At present, no pharmacotherapy has ever been approved by the FDA for the treatment of this disorder.

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of revenue generating products consisting of pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Upcoming Symposium to Bridge the Gap between Osteoporosis Research and its Applications to Clinical Practice with Focus on Secondary Osteoporosis, Osteoporosis in Men, and Lessons from Space Travel for Improving Bone Health
2. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
3. GlobalMedia Provides Free Grant Writing and Application Assistance to Healthcare Providers and Professionals Seeking Their Share of Billions in Economic Stimulus Dollars
4. CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals
5. Hollow gold nanospheres show promise for biomedical and other applications
6. Call for Presentations: Applications of High-Power Semiconductor Lasers Conference & Exhibit
7. FDA Clears Cellectars IND Application for Lead Drug Candidate
8. FDA Halts New Applications From Indian Drug Makers Plant
9. CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application
10. Nephros Provides Update on 510k Applications
11. IMRIS announces development program for MR guided radiation and interventional applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy ... industry-leading compliance software, The Guard®, has helped another long-time client pass their Department ... and properly satisfy the law. , Thanks to the help of the Compliancy ...
(Date:9/20/2017)... ... 2017 , ... The Honey Pot Company is thrilled to ... to ignite conversation via social media and word-of-mouth regarding vaginal health, human rights ... “Humans with Vaginas” month, releasing a video celebrating the power of strong voices ...
(Date:9/20/2017)... ... 2017 , ... Medicare doesn’t have the authority to negotiate ... their prescription drugs, according to a new comparison of drug plans by ... there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare policy ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “The Trials I ... and tribulations as he emotionally pens his aspirations and goals to better one’s life ... published author, Jimmy Green, while searching in all the wrong places, found a love ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. That’s ... and rolled up their sleeves to help with relief efforts. The team picked up ... of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms have ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a leader ... will host an educational session focused on the role ... (CLABSI) prevention at the 2017 Annual Scientific Meeting of ... take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s Prevantics® ...
(Date:9/5/2017)... Sept. 5, 2017  Getinge, a leading global ... vibrant charitable donation program -- "Color for the ... heart defect research by The Children,s Heart Foundation. ... general public are encouraged to download a coloring ... completed artwork to the gallery on the website. ...
(Date:9/1/2017)... -- Bayer will present the latest research from across its growing ... 2017 Congress, September 8-12 in Madrid, Spain ... data on Bayer,s marketed portfolio and late-stage compounds as well ... "We value the opportunity to meet ... ESMO," said Carsten Brunn , Head of Pharmaceuticals, Americas ...
Breaking Medicine Technology: